Engineering T cells for cancer: our synthetic future.
作者信息
Vonderheide Robert H, June Carl H
机构信息
Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Immunol Rev. 2014 Jan;257(1):7-13. doi: 10.1111/imr.12143.
Abstract
摘要
相似文献
1
Engineering T cells for cancer: our synthetic future.工程化改造用于癌症治疗的T细胞：我们的合成未来。
Immunol Rev. 2014 Jan;257(1):7-13. doi: 10.1111/imr.12143.
2
Advances in T-cell Immunotherapies.T 细胞免疫疗法的进展。
Hematol Oncol Clin North Am. 2019 Oct;33(5):825-837. doi: 10.1016/j.hoc.2019.05.006. Epub 2019 Jul 4.
3
Adoptive T cell therapy: points to consider.过继性 T 细胞疗法：需要考虑的要点。
Curr Opin Immunol. 2018 Apr;51:197-203. doi: 10.1016/j.coi.2018.04.007. Epub 2018 May 2.
4
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.基于 T 细胞的免疫疗法：过继细胞转移和检查点抑制。
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
5
The use of endogenous T cells for adoptive transfer.内源性 T 细胞的过继转移。
Immunol Rev. 2014 Jan;257(1):250-63. doi: 10.1111/imr.12134.
6
Adoptive cell therapy: Honing that killer instinct.过继性细胞疗法：磨砺杀手本能。
Nature. 2013 Dec 19;504(7480):S13-5. doi: 10.1038/504S13a.
7
Principles of adoptive T cell therapy in cancer.癌症过继性 T 细胞治疗的原则。
Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5.
8
TCR repertoires of intratumoral T-cell subsets.肿瘤内 T 细胞亚群的 TCR 谱。
Immunol Rev. 2014 Jan;257(1):72-82. doi: 10.1111/imr.12140.
9
Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy.天然存在的近端 TCR 信号遗传改变及其对癌症免疫治疗的影响。
Front Immunol. 2021 May 3;12:658611. doi: 10.3389/fimmu.2021.658611. eCollection 2021.
10
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.使用肿瘤浸润性T细胞和基因工程化TCR-T细胞的T细胞过继性免疫疗法。
Int Immunol. 2016 Jul;28(7):349-53. doi: 10.1093/intimm/dxw022. Epub 2016 Apr 28.
引用本文的文献
1
Frequency and Functional Characterization of Germline Variants in Myeloid Neoplasms.髓系肿瘤中胚系变异的频率及功能特征
Hum Mutat. 2023 Jun 2;2023:4738660. doi: 10.1155/2023/4738660. eCollection 2023.
2
Generation of autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy.用于癌症免疫治疗的自体造血干细胞衍生T淋巴细胞的生成。
Heliyon. 2024 Sep 25;10(19):e38447. doi: 10.1016/j.heliyon.2024.e38447. eCollection 2024 Oct 15.
3
Design and development of engineered receptors for cell and tissue engineering.用于细胞和组织工程的工程受体的设计与开发。
Curr Opin Syst Biol. 2021 Dec;28. doi: 10.1016/j.coisb.2021.100363. Epub 2021 Aug 3.
4
Strategies targeting FLT3 beyond the kinase inhibitors.针对 FLT3 的激酶抑制剂以外的策略。
Pharmacol Ther. 2021 Sep;225:107844. doi: 10.1016/j.pharmthera.2021.107844. Epub 2021 Mar 31.
5
APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.APDL1-CART 细胞对白血病细胞表现出强烈的 PD-L1 特异性活性。
Aging (Albany NY). 2021 Feb 26;13(5):7199-7210. doi: 10.18632/aging.202578.
6
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.上皮性卵巢癌与免疫系统：生物学、相互作用、挑战及免疫治疗的潜在进展
J Clin Med. 2020 Sep 14;9(9):2967. doi: 10.3390/jcm9092967.
7
Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting.通过磁靶向提高过继性细胞转移疗法中效应细胞在肿瘤中的滞留率
Pharmaceutics. 2020 Aug 27;12(9):812. doi: 10.3390/pharmaceutics12090812.
8
The Impact of Varying Cooling and Thawing Rates on the Quality of Cryopreserved Human Peripheral Blood T Cells.不同冷却和复温速率对冷冻保存的人外周血 T 细胞质量的影响。
Sci Rep. 2019 Mar 4;9(1):3417. doi: 10.1038/s41598-019-39957-x.
9
Approaches for generation of anti-leukemia specific T cells.产生抗白血病特异性T细胞的方法。
Cell Regen. 2018 Nov 2;7(2):40-44. doi: 10.1016/j.cr.2018.09.002. eCollection 2018 Dec.
10
Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.CD4+T 细胞改变肿瘤代谢导致 TNF-α 依赖性氧化应激加剧和肿瘤细胞死亡。
Cell Metab. 2018 Aug 7;28(2):228-242.e6. doi: 10.1016/j.cmet.2018.05.012. Epub 2018 Jun 7.
本文引用的文献
1
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.表达嵌合抗原受体的 T 细胞可导致人类过敏反应。
Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.
2
Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.在基于细胞的免疫疗法中，解耦 T 细胞扩增与效应细胞分化。
Immunol Rev. 2014 Jan;257(1):264-276. doi: 10.1111/imr.12135.
3
The use of endogenous T cells for adoptive transfer.内源性 T 细胞的过继转移。
Immunol Rev. 2014 Jan;257(1):250-63. doi: 10.1111/imr.12134.
4
Hematopoietic stem cells for cancer immunotherapy.用于癌症免疫疗法的造血干细胞。
Immunol Rev. 2014 Jan;257(1):237-49. doi: 10.1111/imr.12128.
5
Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.利用基因工程改造供者 T 细胞以优化 MHC 屏障跨越的移植物抗肿瘤效应。
Immunol Rev. 2014 Jan;257(1):226-36. doi: 10.1111/imr.12142.
6
Rapamycin-resistant effector T-cell therapy.雷帕霉素耐药效应 T 细胞治疗。
Immunol Rev. 2014 Jan;257(1):210-25. doi: 10.1111/imr.12127.
7
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.基于人类细胞的人工抗原呈递细胞用于癌症免疫治疗。
Immunol Rev. 2014 Jan;257(1):191-209. doi: 10.1111/imr.12129.
8
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.利用睡眠美人基因进行基因治疗，以基因修饰临床级 T 细胞来靶向 CD19 的新方法。
Immunol Rev. 2014 Jan;257(1):181-90. doi: 10.1111/imr.12137.
9
Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.异基因造血干细胞移植中基因修饰淋巴细胞的过继免疫治疗。
Immunol Rev. 2014 Jan;257(1):165-80. doi: 10.1111/imr.12130.
10
Re-adapting T cells for cancer therapy: from mouse models to clinical trials.重新改造 T 细胞用于癌症治疗：从小鼠模型到临床试验。
Immunol Rev. 2014 Jan;257(1):145-64. doi: 10.1111/imr.12141.
Zotero 插件